A Phase I double-blind, placebo-controlled, single ascending dose study for LX-9211 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs LX 9211 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man; Pharmacokinetics
- 08 Nov 2017 According to a Lexicon Pharmaceuticals media release, data from this trial is expected in 2018.
- 27 Sep 2017 According to a Lexicon Pharmaceuticals media release, the company has initiated dosing in a Phase I study.
- 27 Sep 2017 Status changed from planning to recruiting, according to a Lexicon Pharmaceuticals media release.